Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
GSK3β regulates physiological migration of stem/progenitor cells via cytoskeletal rearrangement
Kfir Lapid, … , Massimo Zollo, Tsvee Lapidot
Kfir Lapid, … , Massimo Zollo, Tsvee Lapidot
Published March 8, 2013
Citation Information: J Clin Invest. 2013;123(4):1705-1717. https://doi.org/10.1172/JCI64149.
View: Text | PDF | Corrigendum
Research Article Hematology

GSK3β regulates physiological migration of stem/progenitor cells via cytoskeletal rearrangement

  • Text
  • PDF
Abstract

Regulation of hematopoietic stem and progenitor cell (HSPC) steady-state egress from the bone marrow (BM) to the circulation is poorly understood. While glycogen synthase kinase-3β (GSK3β) is known to participate in HSPC proliferation, we revealed an unexpected role in the preferential regulation of CXCL12-induced migration and steady-state egress of murine HSPCs, including long-term repopulating HSCs, over mature leukocytes. HSPC egress, regulated by circadian rhythms of CXCL12 and CXCR4 levels, correlated with dynamic expression of GSK3β in the BM. Nevertheless, GSK3β signaling was CXCL12/CXCR4 independent, suggesting that synchronization of both pathways is required for HSPC motility. Chemotaxis of HSPCs expressing higher levels of GSK3β compared with mature cells was selectively enhanced by stem cell factor–induced activation of GSK3β. Moreover, HSPC motility was regulated by norepinephrine and insulin-like growth factor-1 (IGF-1), which increased or reduced, respectively, GSK3β expression in BM HSPCs and their subsequent egress. Mechanistically, GSK3β signaling promoted preferential HSPC migration by regulating actin rearrangement and microtubuli turnover, including CXCL12-induced actin polarization and polymerization. Our study identifies a previously unknown role for GSK3β in physiological HSPC motility, dictating an active, rather than a passive, nature for homeostatic egress from the BM reservoir to the blood circulation.

Authors

Kfir Lapid, Tomer Itkin, Gabriele D’Uva, Yossi Ovadya, Aya Ludin, Giulia Caglio, Alexander Kalinkovich, Karin Golan, Ziv Porat, Massimo Zollo, Tsvee Lapidot

×

Figure 8

GSK3β signaling regulates MT turnover in HSPCs.

Options: View larger image (or click on image) Download as PowerPoint
GSK3β signaling regulates MT turnover in HSPCs.
(A) Total BM cells were ...
(A) Total BM cells were pretreated with 1 μM BIO-A or equivalent DMSO for 1 hour and the content of acetylated tubulin (fold change) was determined by flow cytometry in LK cells (n = 7), and in CD34– LSK cells (n = 5). (B and C) BM MNCs or Lin– BM cells were pretreated with 1 μM BIO-A or equivalent DMSO for 1 hour, after which they were treated with nocodazole (ND, low concentration of 0.5–1 μM, or high concentration of 10 μM) or equivalent DMSO for 15 minutes and then loaded into Transwells. Migration of LK cells (B) or CD34– LSK cells (C) toward 125 ng/ml CXCL12 was assessed for 2 hours (n = 5–6). *P < 0.05 and **P < 0.01 compared with control; #P < 0.05 compared with BIO-A treatment; and ##P < 0.01 compared with CXCL12 treatment. NS, nonsignificant.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts